Why do prostate cancers stop responding to hormone therapy?
11 May 2026
Why do prostate cancers stop responding to hormone therapy?
Research Updates
Leading cancer charity launches new research drive to close Black men’s prostate cancer gap
21 April 2026
Leading cancer charity launches new research drive to close Black men’s prostate cancer gap
Leading cancer charities team up to tackle the spread of breast and prostate cancers to the bones
27 January 2026
Leading cancer charities team up to tackle the spread of breast and prostate cancers to the bones
Looking at the impact of Social Identities and Demographic factors on the Quality of Life for those living beyond cancer
6 December 2024
Looking at the impact of Social Identities and Demographic factors on the Quality of Life for those living beyond cancer
Exploring the relationship between childhood adversity and prostate cancer
7 October 2024
Exploring the relationship between childhood adversity and prostate cancer
Scottish Medical Consortium approves Olaparib for use in NHS Scotland
14 March 2024
Scottish Medical Consortium approves Olaparib for use in NHS Scotland
NICE issues Final Draft Guidance recommending Lynparza (Olaparib) with abiraterone for patients with untreated hormone-relapsed metastatic prostate cancer
21 December 2023
NICE issues Final Draft Guidance recommending Lynparza (Olaparib) with abiraterone for patients with untreated hormone-relapsed metastatic prostate cancer
Government announces major prostate cancer screening trial to end needless prostate deaths
21 November 2023
Government announces major prostate cancer screening trial to end needless prostate deaths
Darolutamide with Docetaxel approved for treatment of mHSPC in Scotland
9 October 2023
Darolutamide with Docetaxel approved for treatment of mHSPC in Scotland
Exploring men’s psychological adjustment to prostate cancer
8 August 2023
Exploring men’s psychological adjustment to prostate cancer
NICE recommends darolutamide with androgen deprivation therapy and docetaxel for patients with hormone-sensitive metastatic prostate cancer
18 May 2023
NICE recommends darolutamide with androgen deprivation therapy and docetaxel for patients with hormone-sensitive metastatic prostate cancer
Load more